SCHEDULE: Iroquois Capital Maintains 9.99% Stake in Petros Pharma
Beneficial Ownership Disclosure
Iroquois Capital Management and its principals disclose a continued 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc., limited by beneficial ownership blockers.
Summary
- Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page collectively reported a 9.99% beneficial ownership stake in Petros Pharmaceuticals, Inc. Common Stock.
- The beneficial ownership is capped at 9.99% due to 'Beneficial Ownership Blockers' on certain Warrants and Preferred Shares, preventing full exercise or conversion.
- As of June 30, 2025, the reporting persons beneficially owned 3,279,192 shares (Iroquois Capital and Kimberly Page) and 3,313,704 shares (Richard Abbe), representing 9.99% of the class.
- The ownership includes 1,269,057 shares of Common Stock held directly by Iroquois Master Fund and 34,512 shares by ICIG.
- It also includes Warrants exercisable for up to 24,690,507 shares (Iroquois Master Fund) and 6,468,098 shares (ICIG), subject to 4.99% or 9.99% beneficial ownership blockers.
- Additionally, 369,031 shares (IMF) and 257,526 shares (ICIG) are issuable upon conversion of Preferred Stock at a $0.1269 conversion price, subject to a 4.99% blocker.
- The reported 9.99% beneficial ownership is based on 31,160,086 outstanding common shares as of May 14, 2025, plus 2,010,135 shares issuable upon exercise/conversion after applying the blockers.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, with no inherent positive or negative sentiment regarding company performance or outlook. The sentiment is neutral.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake in a publicly traded company, common among investment funds and their principals. The use of beneficial ownership blockers is a common mechanism to manage ownership percentages and avoid triggering certain regulatory thresholds or control implications.
Stakeholder Impact
- Existing shareholders: The beneficial ownership blockers limit the immediate dilutive impact from the conversion of Preferred Shares and exercise of Warrants held by the reporting persons, as their stake is capped at 9.99%.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of outstanding common stock count (31,160,086 shares) as reported in Issuer's Form 10-Q. |
| 05/15/2025 | Date of Issuer's Quarterly Report on Form 10-Q filing with the SEC. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 08/14/2025 | Signature date of the Schedule 13G filing. |
Keywords
Petros Pharmaceuticals, Iroquois Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Warrants, Preferred Shares, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.